Telix Completes Patient Enrollment In BiPASS Trial, Aligns With FDA On NDA Filing; Stock Up

(RTTNews) - Telix Pharmaceuticals Limited (TLX), a commercial-stage biopharmaceutical company, on Wednesday reported completion of patient enrollment in the Phase 3 BiPASS study, evaluating its commercial PSMA-PET imaging agents, Illuccix and Gozellix, for Prostate cancer in the